Cargando…
Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience
Epoprostenol was the first therapy to be approved for the treatment of pulmonary arterial hypertension (PAH). In the 20 years since the introduction of this prostacyclin analogue, the outlook for patients with PAH has improved, with survival rates now double those from the era before the development...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Respiratory Society
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489058/ https://www.ncbi.nlm.nih.gov/pubmed/28096285 http://dx.doi.org/10.1183/16000617.0055-2016 |